

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims.

1-41. (Cancelled)

42. (Currently Amended) A method of treating a patient having an injury to or a disorder of an eye, said injury or disorder comprising degeneration of a photoreceptor cell, said method comprising administering to a patient ~~a therapeutically effective amount of a~~ polypeptide comprising amino acids 108 to 233 of SEQ ID NO:2, in an amount sufficient to proliferate the photoreceptor cell.

43. (Previously Presented) The method of claim 42, wherein the polypeptide is attached to a water soluble polymer.

44. (Previously Presented) The method of claim 43, wherein the water soluble polymer is polyethylene glycol.

45. (Previously Presented) The method of claim 42, wherein the polypeptide is administered as a pharmaceutical composition.

46. (Previously Presented) The method of claim 45, wherein the polypeptide pharmaceutical composition is a sustained-release pharmaceutical composition.

47. (Previously Presented) The method of claim 42, wherein the polypeptide is administered as a topical pharmaceutical composition.

48. (Previously Presented) The method of claim 42, wherein the polypeptide is administered as an oral pharmaceutical composition.

49. (Previously Presented) The method of claim 42, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

50. **(Previously Presented)** The method of claim 42, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

51. **(Previously Presented)** The method of claim 50, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.

52. **(Previously Presented)** The method of claim 42, wherein the polypeptide comprises amino acids 80 to 202 of SEQ ID NO:2.

53. **(Previously Presented)** The method of claim 52, wherein the polypeptide is attached to a water soluble polymer.

54. **(Previously Presented)** The method of claim 53, wherein the water soluble polymer is polyethylene glycol.

55. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered as a pharmaceutical composition.

56. **(Previously Presented)** The method of claim 55, wherein the polypeptide pharmaceutical composition is a sustained-release pharmaceutical composition.

57. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered as a topical pharmaceutical composition.

58. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered as an oral pharmaceutical composition.

59. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

60. **(Previously Presented)** The method of claim 52, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.
61. **(Previously Presented)** The method of claim 60, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.
62. **(Previously Presented)** The method of claim 42, wherein the polypeptide comprises amino acids 9 to 396 of SEQ ID NO:2.
63. **(Previously Presented)** The method of claim 62, wherein the polypeptide is attached to a water soluble polymer.
64. **(Previously Presented)** The method of claim 63, wherein the water soluble polymer is polyethylene glycol.
65. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered as a pharmaceutical composition.
66. **(Previously Presented)** The method of claim 65, wherein the polypeptide pharmaceutical composition is a sustained-release pharmaceutical composition.
67. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered as a topical pharmaceutical composition.
68. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered as an oral pharmaceutical composition.
69. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

70. **(Previously Presented)** The method of claim 62, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

71. **(Previously Presented)** The method of claim 70, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.

72. **(New)** The method of claim 42, wherein the injury or disorder is selected from the group consisting of angioid streaks, retinitis pigmentosa, Kearns's Syndrome, pigment pattern dystrophies, retinal perforations, retinitis, chorioretinitis, cytomegalovirus retinitis, acute retinal necrosis syndrome, central alveolar choroidal dystrophy, dominant drusen, hereditary hemorrhagic macular dystrophy, North Carolina macular dystrophy, pericentral choroidal dystrophy, adult foveomacular dystrophy, benign concentric annular macular dystrophy, central areolar pigment epithelial dystrophy, congenital macular coloboma, dominantly inherited cystoid macular edema, familial foveal retinoschisis, fenestrated sheen macular dystrophy, progressive foveal dystrophy, slowly progressive macular dystrophy, Sorsby's pseudoinflammatory dystrophy, cone-rod dystrophy, progressive cone dystrophy, Leber's congenital amaurosis, Goldman-Favre syndrome, Bardet-Biedl syndrome, Bassen-Kornzweig syndrome, Best disease, choroidemia, gyrate atrophy, congenital amaurosis, Refsum syndrome, Stargardt disease and Usher syndrome.

73. **(New)** The method of claim 42, wherein the injury or disorder is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies, ischemic retinopathies, retinal detachment and traumatic retinopathy.